TEVA•benzinga•
Truist Securities Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $25
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 28, 2025 by benzinga